Information from a section 4 post-marketing surveillance examine of SB2, an infliximab biosimilar, is offering clinicians with new perception into the protection and...
Patent litigators from Fish & Richardson, an mental property legislation agency, regaled audiences throughout a webinar, entitled “Biosimilars: 2022 12 months-in-Assessment,” protecting all...
